Publications
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
May 23, 2022
A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells
April 14, 2021
© 2022 Tcelltech GmbH. All rights reserved.
Responsible Provider in accordance with § 5 of the German Telemedia Act (TMG):
Tcelltech GmbH
Cubex One
Franz-Volhard-Straße 5
68168 Mannheim
Germany
T + 49 178 730 730 2
Management:
Michael Platten, Richard Harbottle, Edward Green, Mathias Turwitt
Commercial register/register number
District Court of Mannheim HRB 745 600
VAT number
not yet available